IVIM & OLINK in Sarcoma

NCT05950594 · tracked via the Priya Life Science Canada tracker

Sponsor

University Health Network, Toronto

Phase

Phase 2

Started

2024-03-05

Last updated

2026-03-16

Condition(s) studied

Soft Tissue Sarcoma

Investigational drug(s) / intervention(s)

RadiotherapySurgery

Radiotherapy: Standard of care pre-operative radiotherapy

Surgery: Standard of care definitive surgery

Study summary

The hypoxia \> metastasis axis suggests that a DWI-based biomarker of hypoxia incorporating IVIM may be able to predict metastasis in STS patients, ultimately enabling stratification for personalized treatments at the time of diagnostic (MR) imaging, without adding an excessive burden to the patient or clinical workflow (typical DWI/IVIM sequences can be acquired acquired in approximately 5 minutes).

Eligibility

Sex

ALL

Min age

18 Years

Max age

100 Years

Healthy volunteers

Inclusion Criteria: * Age ≥ 18 years * Ability to understand and the willingness to sign a written informed consent document * Grade 2 or 3 soft tissue sarcoma greater than 5 cm in largest dimension Exclusion Criteria: * Contraindication to MRI scan as per current institutional guidelines (for patients requiring MRI)

Primary outcome measure(s)

Identify image-derived, plasma-derived biomarkers of hypoxia — 3 years
Image-derived, plasma-derived biomarkers of hypoxia (such as HIF-1alpha, VEGF, osteopontin) acquired before radiation therapy will be assessed for correlation to distant metastasis-free survival.

Trial sites (1)

Facility	City	Region	Status
University Health Network	Toronto	Ontario	Recruiting

More University Health Network, Toronto trials in Canada

meChANisms and sAfety of SGLT2 Inhibition in peRitoneal dialYsis Recruiting

Comprehensive Genomic Profiling of Colorectal Cancer Patients With Isolated Liver Metastases to Understand Response & Resistance to Cancer Therapy Active, not recruiting

CBF and NCF Changes With Brain Radiation Active, not recruiting

A Study to Evaluate Zanubrutinib and Tislelizumab in Progressive Lymphoma Post CAR-T Recruiting

Outcomes Post Treatment: Impact on Motor Impairment of Sleep Efficiency in SCI (OPTIMISE SCI Trial) Recruiting

Other trials for the same condition

Circulating Tumor DNA in Soft Tissue Sarcoma Recruiting

In Vivo Lung Perfusion for Pulmonary Metastases of Sarcoma Recruiting

Surveillance AFter Extremity Tumor surgerY Active, not recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05950594 on ClinicalTrials.gov ↗ ← All trials in Canada